for Disease Control and Prevention and others have continued efforts to reduce inappropriate antibiotic prescribing. [3] [4] [5] To measure changes in antibiotic prescribing for adults with sore throat, we conducted a cross-sectional analysis of ambulatory visits in the United States.
Methods | The National Center for Health Statistics institutional review board approved the protocols for the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS), including a waiver of the requirement for patient informed consent. The NAMCS and NHAMCS are annual, nationally representative, multistage probability surveys of ambulatory care in the United States 6 that collect information on physicians and practices as well as visit-level data, including patient demographics, reasons for visits, diagnoses, and medications. Each visit in the NAMCS/NHAMCS is weighted to allow extrapolation to national estimates.
For the years 1997 to 2010, we included "new problem" visits by adults 18 years or older with a primary reason for visit of throat soreness or pain (Reason for Visit code 1455) who made a primary care or emergency department (ED) visit. We excluded patients with injuries, immunosuppression, or concomitant infectious diagnoses. There were 8191 sampled sore throat visits meeting the inclusion criteria. We identified and classified antibiotics as penicillin, amoxicillin, erythromycin, azithromycin, other second-line antibiotics, and all other antibiotics.
We calculated standard errors (SEs) for all results using the survey package in R, version 2.11.1 (R Project), combining data into 2-year periods, and clearly indicating when estimates were below the threshold of reliable measurement (<30 sampled visits or a relative SE > 30%).
Results | Between 1997 and 2010, the 8191 sampled sore throat visits represented 92 million estimated visits by adults to primary care practices and EDs in the United States (Table) . Sore throat visits decreased from 7.5% of primary care visits in 1997 to 4.3% of visits in 2010 (P = .006). There was no change in the proportion of sore throat visits to EDs: 2.2% in 1997 and 2.3% in 2010 (P = .18). Physicians prescribed antibiotics at 60% of visits (95% CI, 57%-63%). The overall national antibiotic prescribing rate did not change ( Figure) . Penicillin prescribing remained stable at 9% of Editor's Note page 140 cephalosporins, clarithromycin, and clindamycin. The most commonly prescribed nonrecommended antibiotics were cephalosporins (37% of category), penicillin/β-lactamase combinations (27%), and fluoroquinolones (13%). For trends, P = .27 for penicillin; P < .001 for azithromycin; P = .33 for amoxicillin; and P = .37 for nonrecommended antibiotics.
Discussion | Our analysis has limitations. First, we do not have clinical data to know if individual antibiotic prescriptions are appropriate. Second, the NAMCS/NHAMCS does not capture patients managed outside of clinic or ED visits. Third, several of our 2-year estimates were below the threshold of reliable measurement. Antibiotic prescribing to patients who are unlikely to benefit is not benign. All antibiotic prescribing increases the prevalence of antibiotic-resistant bacteria. The financial cost of unnecessary antibiotic prescribing to adults with sore throat in the United States from 1997 to 2010 was conservatively $500 million. However, antibiotics might have been up to 40-times more expensive. For individuals, antibiotic prescribing leads to patients developing diarrhea in 5% to 25% of cases; at least 1 in 1000 patients visits an ED for a serious adverse drug event.
In conclusion, despite decades of effort, we found only incremental improvement in antibiotic prescribing for adults making a visit with sore throat. Combining our previous and present analyses, the antibiotic prescribing rate dropped from roughly 80% to 70% around 1993 and dropped again around 2000 to 60%, where it has remained stable. 2 This still far exceeds the 10% prevalence of GAS among adults seeking care for sore throat. The prescription of broader-spectrum, more expensive antibiotics, especially azithromycin, was common. Prescribing of penicillin, which is guideline-recommended, inexpensive, welltolerated, and to which GAS is universally susceptible, remained infrequent.
Choosing Wisely, and Soon
Barnett and Linder report the sobering news that despite valiant efforts by the Centers for Disease Control and Prevention and others to reduce inappropriate prescription o f a n t i b i o t i c s f o r s o r e throats in the last 20 years, little to no progress has been made. Even though only about 10% of sore throats are due to group A Streptococcus (GAS) infection, 60% of patients with sore throats were treated with antibiotics. And instead of narrowing the antibiotic spectrum, the use of azithromycin grew, while the use of penicillin declined since 1998.
On an individual level, use of antibiotics for patients without GAS infection exposes them to adverse effects without any benefit. On a societal level, the increase in the use of antibiotics, particularly the broader-spectrum ones, accelerates the development of resistant organisms. Hopefully, implementation of the principles of Choosing Wisely, where in 2011 the pediatricians admonished not to use antibiotics in the absence of a confirmed diagnosis of strep, will start to lower inappropriate use soon. 
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